Hoth Therapeutics

Inactive

HOTH (NCM)

Hoth Therapeutics is a clinical-stage biopharma focused on unmet medical needs in the United States. It develops HT-001, a topical for rash and skin disorders linked to EGFR inhibitor therapy; HT-KIT for mast cell cancers and anaphylaxis; HT-TBI for traumatic brain injury and ischemic stroke; HT-ALZ for Alzheimer's and neuroinflammation; and HT-004 for asthma and allergies by inhalation. BioLexa Platform (eczema) and HT-005 for lupus are in earlier stages. Licenses with several universities and companies; founded 2017; based in Hoboken, NJ.